Clinical trials: Psychotic Disorder
Schizophrenia, Schizophreniform Disorder
Biomarkers in First Episode Schizophrenia
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
- Trial name
- NCT02033382
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Schizophrenia, Schizo-affective Disorder
Illness Management and Recovery for Veterans With Severe Mental Illness
The President's New Freedom Commission on Mental Health has called for a transformation of the mental health system to partner with consumers of those services in delivering effective interventions focused on recovery, and the…
- Trial name
- NCT00515671
- Testing
- Illness Management and Recovery, Problem Solving
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
- Trial name
- NCT01677377
- Testing
- Risperidone, RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Indivior Inc.
Schizophrenia, Schizoaffective Disorder
Development of a Mobile System for Self-management of Schizophrenia (SOS)
This 2-arm clinical trial piloted a mobile Self-Management of Schizophrenia (SOS) system that administers interventions targeting persistent symptoms of psychosis, social dysfunction, and medication adherence.
- Trial name
- NCT01969500
- Testing
- Mobile Application, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia and Related Disorders
Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
The Repetitive Transcranial Magnetic Stimulation (rTMS) is a type of brain stimulation that uses a magnet to change activity in the brain.
- Trial name
- NCT05319080
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Health, Subjective, Disability, Evaluation
Ageing and Health. Spanish Longitudinal Study
Ageing with Health is a longitudinal cohort study aimed to examine trajectories of health, disability and wellbeing and their determinants for Spanish ageing population.
- Conditions
- Health, Subjective, Disability, Evaluation, Chronic Disease, Mental Disorder
- Trial name
- NCT03343886
- Where
- 3 sites in Spain
- Volunteers
- 7,755 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Schizophrenia
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia
This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia.
- Trial name
- NCT00611806
- Testing
- Folic Acid, B12
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.
- Trial name
- NCT01377233
- Testing
- Zicronapine open-label lead-in 10 mg daily, Zicronapine 10 mg daily, Zicronapine 20 mg once weekly
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- H. Lundbeck A/S
Mental Health Issues, Bipolar Disorder
Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma
This study will use a systematic music therapy intervention on patients with mental illness trying to help them with their internalized stigma.
- Conditions
- Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05723328
- Testing
- Group Music Therapy Advocacy Recording Intervention (MTAR)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Hackensack Meridian Health
Schizophrenia
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of long acting injectable (LAI) risperidone and oral risperidone treatment on participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00992407
- Testing
- Risperidone long acting injectables, Risperidone tablets
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Multicenter, Open-label, Safety and Tolerability Study
This will be a multicenter, 52 week, open label study to assess the safety and tolerability of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study will be conducted on an outpatient basis.
- Trial name
- STEP 210 (NCT01649557)
- Testing
- OPC-34712
- Where
- 68 sites in United States, Bulgaria and 10 more
- Volunteers
- 244 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Confirmatory Study of DSP-5423P in Patients With Schizophrenia
The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.
- Trial name
- NCT02287584
- Testing
- DSP-5423P 40mg, DSP-5423P 80mg, DSP-5423P Active-to-Flex
- Where
- 8 sites in China, Japan and 6 more
- Volunteers
- 580 people
- Sponsor
- Sumitomo Pharma Co., Ltd.